Request for information about the pharmaceutical Tafamidis and its use in the control of amyloidosis.
Information about PHARMAC funding high-cost medicines.
What medicines/ingredients are more expensive (as a result of COVID-19) and by how much have they increased?
NPPA Applications for the last 5 years and the lamotrigine exceptional circumstances applications
We are pleased to announce a decision to award sole supply of infliximab, a biologic medicine used to treat a range of inflammatory and autoimmune conditions, from 1 September 2020.
The number of complaints received by PHARMAC about funding.
Nationwide Special Authority initiations and renewals by (immunology) indication for adalimumab, etanercept, secukinumab, infliximab, tocilizumab and rituximab, by month from October 2019 to April 2020.
Funding of methylphenidate or similar stimulant medications, for Attention Deficit Hyperactivity Disorder (ADHD).
Special Authority data on pembrolizumab and nivolumab, from Jan 2020 to May 2020.
PHARMAC invites registrations of interest (ROI) for the supply of various pharmaceuticals to the New Zealand subsidised market.
All proposals must be submitted to PHARMAC via the Government Electronic Tenders Service (GETS) (www.gets.govt.nz) no later than 5pm NZT Tuesday 7 July 2020 - RFx ID 22841075.
If you have any questions about this ROI, please post these on the Government Electronic Tenders Service (www.gets.govt.nz).
Answers to questions will be provided through the Government Electronic Tenders Service (GETS). PHARMAC will also post any addenda through GETS. We encourage interested organisations to register with GETS and subscribe to this ROI to be kept up to date.
We're seeking feedback on the longer-term funding arrangements for the pharmaceuticals we amended to help with the response to COVID-19.
Consultation closes: 5 pm Friday 3 July 2020.
PHARMAC would like to advise all interested parties that there will be a delay in the decision on a proposal to list mifepristone in Section B of the Pharmaceutical Schedule from 1 July 2020 and amend the listing of misoprostol in Section B of the Pharmaceutical Schedule enabling it to be supplied on a Practitioners’ Supply Order (PSO) from 1 July 2020.
PHARMAC is seeking feedback on a proposal to list rehabilitation equipment, patient positioning products and supports supplied by At Therapy Limited and Morton & Perry Limited in Part III of Section H of the Pharmaceutical Schedule from 1 September 2020.
Closes: 4pm Wednesday 15 July 2020.
PHARMAC is seeking feedback on a proposal to list medical devices supplied by Stryker New Zealand Limited in Part III of Section H of the Pharmaceutical Schedule from 1 August 2020.
Closes: 4pm Thursday 2 July 2020.
Information regarding levothyroxine supply in New Zealand.
Ibrutinib funding requests
An independent review on the lamotrigine sole-supply decision has found that PHARMAC’s processes were evidence based and robust, and of a high standard.
PHARMAC's budget and expenditure on promoting responsible use of medicines.
Request for the information that supported PTAC's consideration of whole thyroid extract and normal and extended release T3 for the treatment of hypothyroidism.
PHARMAC's correspondence in preparing for New Zealand's COVID-19 response.